Seek Labs won the Innovation winner award in the BioTech/Therapeutics category for Sequence Ablation Technology.
Published
Signal category
Presence & Recognition
Quote
“Very honored to accept this award on behalf of our incredible team at Seek Labs. Thank you to Utah Business for selecting our Sequence Ablation Technology as the Innovation winner in BioTech/Therapeutics category.”
— Alison O'Mahony|Seek Labs team
Company
Seek Labs
Every disease has a sequence. Decode it. Program against it. Target what it can’t change.
- Industry
- Biotechnology Research
- Location
- Salt Lake City, US
- Company size
- 34 employees
Seek Labs is building a programmable disease-response platform. One AI engine. Two deployment paths across therapeutics and diagnostics. A new way to fight disease. • BioSeeker decodes disease-associated genomic sequences and identifies conserved vulnerabilities. • PTAP programs those insights into Sequence Ablation Therapeutics (SAT), a new class of programmable therapeutics. • SeekIt brings molecular detection to the point of need. Decode. Program. Resolve. We’ve already started. 145+ diseases decoded by BioSeeker. When a new pathogen emerges, Seek Labs is not at day zero. This is a platform, not a single drug, built for infectious disease, global health, and emerging threats. Learn more at www.seek.labs.com.
Founded 2016